Abstract: Sterol and stanol phosphorylnitro derivatives and their use in treating or preventing cardiovascular disease, its underlying conditions and other disorders are disclosed. The disclosed compounds include a phosphate linker, at least one moiety that releases nitric oxide (NO), and a sterol or stanol moiety. Some compounds additionally include an ascorbyl moiety to make the compound more readily soluble in aqueous and non-aqueous media.

Abstract: Sterol and stanol nitro derivatives and their use in treating or preventing cardiovascular disease, its underlying conditions and other disorders are disclosed. The disclosed nitro derivatives are synthesized by ester linkage of a nitric oxide (NO)-releasing moiety to a sterol or stanol compound.

Abstract: A process for isolating and purifying phytosterols and phytostanols from tall oil pitch is disclosed which comprises the following steps:

Abstract: The present invention provides a esterified and subsequently hydrogenated phytosterol composition for use alone or for incorporation into foods, beverages, pharmaceuticals, nutraceuticals, and the like. The composition has the advantage of enhanced solubility/dispersability, increased molar potency and enhanced stability over naturally isolated phytosterol compositions. Methods for the esterification and subsequent hydrogenation of the phytosterols are also provided.

Abstract: A novel process for the fermentation of phytosterol compositions to androstenedione (androst-4-ene-3,17-dione, AD) and/or androstadienedione (androsta-1,4-diene-3,17-dione, ADD) is disclosed. The process utilizes the micro-organism Mycobacterium MB 3683, and selected suitable solubilizing agents such as polypropylene glycol or silicone for solubilizing the phytosterol compositions at high concentrations in the nutrient medium. The innoculum of Mycobacterium MB 3683 is grown in a nutrient medium comprising Refiners molasses and inorganic salts.

Abstract: A method of preventing and/or delaying the onset of Alzheimer's disease in an animal comprises administering to the animal a phytosterol composition. A composition useful for preventing and/or delaying the onset of Alzheimer's disease in an animal comprises a phytosterol composition.

Abstract: Methods are provided for determining whether a subject animal has an increased risk of cardiovascular or related disorder. The level of serum campesterol and beta-sitosterol are determined and a campesterol/beta-sitosterol ratio obtained. The ratio determined for the subject animal is compared with that of a normal control animal and correlated with the risk of cardiovascular or a related disorder.